EUDRACAP® colon

From the upper small intestine to the ileo-colonic region.
Optimize disease treatment efficiency with targeted drug delivery.

Targeted drug delivery to the ileo-colonic region

EUDRACAP® colon is designed for drug products targeted for release in the ileo-colonic region. Like EUDRACAP® enteric, it provides reliable gastric resistance to protect sensitive ingredients.

Reliable protection and delayed release

Dissolution testing of EUDRACAP® colon confirms that no drug release occurs during the acid stage (HCl 0.1N) or at buffer stage at pH 6.8. After conversion to the buffer stage at pH 7.2, release starts.

In comparison to EUDRACAP® enteric, which shows fast release at pH 6.8, EUDRACAP® colon provides significantly more delayed release at a higher pH.

For sensitive drug actives

EUDRACAP® colon provides reliable protection and targeted delivery of sensitive actives like live biotherapeutics, polypeptides and proteins (biologics), and nucleotides.

Target release with EUDRACAP® colon and EUDRACAP® enteric



Dissolution profile using caffeine as model compound





- Live biotherapeutics
- Biologics/proteins
- Nucleotides
- Other sensitive actives

EVONIK
Leading Beyond Chemistry

202408

Evonik Operations GmbH
Health Care Business Line

healthcare@evonik.com
evonik.com/healthcare

EVONIK
Leading Beyond Chemistry